ABVC BioPharma, Inc.

AI-generated fair value estimate for this company.

Method: Net-cash-floor approach (a standard DCF is not meaningful for this pre-revenue/near-zero-revenue clinical-stage biotech): cash of $0.094M versus total debt of $2.89M gives negative net cash of -$2.79M (-$0.11/share on 25.92M shares outstanding), so the balance-sheet floor is effectively $0 under limited liability; added a modest risk-adjusted pipeline value from the disclosed Xinnovation Therapeutics term sheet (up to $20M licensing fees plus 5-12% royalties for ABV-1504/ABV-1505 in China), probability-weighted at approximately 15% chance of collecting roughly half of that over several years (about $1.5M expected value, discounted about 2 years at 15%) giving roughly $1.1-1.3M, or about $0.04-0.05/share.

Reasoning: ABVC is a going-concern-challenged clinical-stage biopharma (current ratio 0.07, working capital -$5.28M, cash burn -$2.69M TTM, 72% YoY share dilution) with no meaningful FCF, so a DCF is not applicable; net cash is already negative, so the only real support for the $0.96 market price is speculative, non-binding pipeline licensing optionality, which this estimate captures conservatively.